Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-019680
Filing Date
2023-05-09
Accepted
2023-05-09 16:13:35
Documents
62
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q achv-20230331.htm   iXBRL 10-Q 2159500
2 EX-31.1 achv-ex31_1.htm EX-31 13370
3 EX-32.1 achv-ex32_1.htm EX-32 7866
4 GRAPHIC img226502045_0.jpg GRAPHIC 92506
  Complete submission text file 0000950170-23-019680.txt   7933841

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT achv-20230331_cal.xml EX-101.CAL 36319
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT achv-20230331_lab.xml EX-101.LAB 419797
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT achv-20230331_def.xml EX-101.DEF 236372
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT achv-20230331_pre.xml EX-101.PRE 314955
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT achv-20230331.xsd EX-101.SCH 54369
56 EXTRACTED XBRL INSTANCE DOCUMENT achv-20230331_htm.xml XML 1360214
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 23902159
SIC: 2835 In Vitro & In Vivo Diagnostic Substances